RS51091B - 2-(amino-supstituisani)-4-aril piramidini i srodna jedinjenja korisna za lečenje inflamatornih bolesti - Google Patents

2-(amino-supstituisani)-4-aril piramidini i srodna jedinjenja korisna za lečenje inflamatornih bolesti

Info

Publication number
RS51091B
RS51091B RSP-2009/0466A RSP20090466A RS51091B RS 51091 B RS51091 B RS 51091B RS P20090466 A RSP20090466 A RS P20090466A RS 51091 B RS51091 B RS 51091B
Authority
RS
Serbia
Prior art keywords
alkyl
phenyl
optionally substituted
halo
procedure
Prior art date
Application number
RSP-2009/0466A
Other languages
English (en)
Serbian (sr)
Inventor
Zhan Shi
Shaowu Chen
Paul E. Fleming
Jane F. Schmidt
John C. Reader
Neal D. Hone
Jefrey P. Ciavarri
Original Assignee
Millennium Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34749013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51091(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc. filed Critical Millennium Pharmaceuticals Inc.
Publication of RS51091B publication Critical patent/RS51091B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RSP-2009/0466A 2004-01-08 2005-01-10 2-(amino-supstituisani)-4-aril piramidini i srodna jedinjenja korisna za lečenje inflamatornih bolesti RS51091B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53489804P 2004-01-08 2004-01-08
PCT/US2005/000663 WO2005066139A2 (en) 2004-01-08 2005-01-10 2-(amino-substituted)-4-aryl pyramidines and related compounds useful for treating inflammatory diseases

Publications (1)

Publication Number Publication Date
RS51091B true RS51091B (sr) 2010-10-31

Family

ID=34749013

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0466A RS51091B (sr) 2004-01-08 2005-01-10 2-(amino-supstituisani)-4-aril piramidini i srodna jedinjenja korisna za lečenje inflamatornih bolesti

Country Status (18)

Country Link
US (2) US7732444B2 (enExample)
EP (2) EP2123647A1 (enExample)
JP (1) JP2007517895A (enExample)
AR (1) AR047185A1 (enExample)
AT (1) ATE437861T1 (enExample)
AU (1) AU2005204060A1 (enExample)
CA (1) CA2559888A1 (enExample)
CY (1) CY1109529T1 (enExample)
DE (1) DE602005015677D1 (enExample)
DK (1) DK1701944T3 (enExample)
ES (1) ES2330863T3 (enExample)
HR (1) HRP20090572T1 (enExample)
PL (1) PL1701944T3 (enExample)
PT (1) PT1701944E (enExample)
RS (1) RS51091B (enExample)
SI (1) SI1701944T1 (enExample)
TW (1) TW200533357A (enExample)
WO (1) WO2005066139A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
WO2005095386A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
JP2009521488A (ja) * 2005-12-21 2009-06-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｋｃ−シータのインヒビターとして有益なピリミジン誘導体
WO2007107543A1 (en) * 2006-03-22 2007-09-27 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
AU2008236679B2 (en) * 2007-04-03 2013-11-28 Fmc Corporation Substituted benzene fungicides
HUE024877T2 (en) * 2007-10-30 2016-02-29 Genentech Inc Antibody purification by cation exchange chromatography
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 ６員芳香環含有化合物
EP2169665B1 (en) 2008-09-25 2018-05-02 LG Electronics Inc. A method and an apparatus for processing a signal
EP2599494A1 (en) * 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
US20130109019A1 (en) * 2010-07-02 2013-05-02 Adrian E. Murillo Hapten conjugates for target detection
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
ES2552989T3 (es) 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
PE20150666A1 (es) 2012-03-01 2015-05-06 Array Biopharma Inc Inhibidores de serina/treonina cinasa
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
CA2882750A1 (en) 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
CA2923765C (en) 2013-09-18 2021-06-29 University Of Canberra Stem cell modulation ii
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
WO2023104744A1 (en) 2021-12-06 2023-06-15 Helmholtz-Zentrum Dresden-Rossendorf E.V. 3-((3-([1,1'-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives and the use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698697A (en) 1995-07-19 1997-12-16 Mitsubishi Chemical Corporation 2-cyanopiperazine and method of producing the same
JP2001526230A (ja) * 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CZ20012350A3 (cs) 1998-12-24 2001-09-12 Aventis Pharmaceuticals Products Inc. Substituované (aminoiminomethyl nebo aminomethyl) benzoheteroarylové sloučeniny
US6492516B1 (en) 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity
WO2001000214A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
DE60039616D1 (de) 1999-08-13 2008-09-04 Vertex Pharma INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
EP1326865B1 (en) 2000-10-12 2009-05-06 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
MXPA03008888A (es) * 2001-03-29 2005-03-07 Vertex Pharma Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas.
DE60214701T2 (de) * 2001-04-13 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
GB0112803D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
MXPA04004166A (es) 2001-11-07 2004-07-08 Hoffmann La Roche Aminopirimidinas y piridinas.
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
WO2003106451A1 (en) * 2002-06-14 2003-12-24 Altana Pharma Ag Substituted diaminopyrimidines
TW200510311A (en) 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
EP1590334B1 (en) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
AU2004229392A1 (en) 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
WO2005095386A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
MXPA06014247A (es) 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
EP1809290A2 (en) * 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
AU2005316312B2 (en) 2004-12-17 2009-10-22 Amgen, Inc. Aminopyrimidine compounds and methods of use
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
DE102005034821A1 (de) * 2005-07-26 2007-02-08 Fleissner Gmbh Voluminöse Faserlaminate und ihre Herstellung
TWM293131U (en) * 2006-01-10 2006-07-01 Shuen Tai Prec Entpr Co Ltd Handheld power hammer

Also Published As

Publication number Publication date
ATE437861T1 (de) 2009-08-15
TW200533357A (en) 2005-10-16
PT1701944E (pt) 2009-11-03
CY1109529T1 (el) 2014-08-13
CA2559888A1 (en) 2005-07-21
SI1701944T1 (sl) 2010-03-31
US8268822B2 (en) 2012-09-18
EP2123647A1 (en) 2009-11-25
US7732444B2 (en) 2010-06-08
WO2005066139A3 (en) 2005-10-13
US20060040968A1 (en) 2006-02-23
ES2330863T3 (es) 2009-12-16
WO2005066139A2 (en) 2005-07-21
US20110071134A1 (en) 2011-03-24
EP1701944A2 (en) 2006-09-20
AR047185A1 (es) 2006-01-11
AU2005204060A1 (en) 2005-07-21
EP1701944B1 (en) 2009-07-29
PL1701944T3 (pl) 2010-01-29
DE602005015677D1 (de) 2009-09-10
JP2007517895A (ja) 2007-07-05
DK1701944T3 (da) 2009-11-09
HRP20090572T1 (hr) 2010-01-31

Similar Documents

Publication Publication Date Title
US8268822B2 (en) 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
TWI816809B (zh) 黑皮質素亞型-2受體(mc2r)拮抗劑及其用途
CN104822373B (zh) 治疗性化合物和组合物
US20100113445A1 (en) Chemical Compounds
RU2671864C2 (ru) N-(4-(азаиндазол-6-ил)-фенил)-сульфонамиды и их применение в качестве лекарственных средств
CA2477505A1 (en) Diamino-pyrimidines and their use as angiogenesis inhibitors
CN101641346B (zh) 作为mglur2拮抗剂的吡啶和嘧啶衍生物
CA2469316A1 (en) Pyrimidine-based compounds useful as gsk-3 inhibitors
CN104540809A (zh) 成纤维细胞生长因子受体的抑制剂
CA2683619A1 (en) Pharmaceutical compounds
BRPI0709007A2 (pt) inibidores de 8-heteroarilpurina mnk2 para tratamento de distúrbios metabólicos
AU2006332694A1 (en) Substituted bis-amide metalloprotease inhibitors
TW200840580A (en) Heterocyclic aspartyl protease inhibitors
BRPI0713328A2 (pt) derivados de piridina e pirazina como inibidores de cinase mnk
RS63418B1 (sr) Kompozicije i metode za proizvodnju jedinjenja pirimidina i piridina sa btk inhibitorskom aktivnošću
HUE035919T2 (en) Macrocyclic pyridazinone derivatives
AU2005295788A1 (en) N-benzenesulfonyl substituted anilino-pyrimidine analogs
MXPA06000051A (es) Pirimidinas utiles como moduladores de canales ionicos dependientes de voltaje.
RS55793B1 (sr) 6-alkinil piridini kao smac mimetici
US7329678B2 (en) Chemical compounds
CN110305125A (zh) 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用
AU2006237365A1 (en) 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2
WO2007076247A1 (en) Pyrimidine derivatives useful as inhibitors of pkc-theta
CN115551845B (zh) Phd抑制剂化合物、组合物和用途
CN112341431A (zh) 作为fgfr4抑制剂的杂环化合物